Drugs / DCTY0801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05802693 | Nov 2023 → Nov 2025 | glioblastoma | Beijing Tsinghua Chang Gung Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DCTY0801 | “DCTY0801 Autologous T lymphocyte injection” NCT05802693 ↗ |
| Known as | DCTY0801 Autologous T lymphocyte injection | “DCTY0801 Autologous T lymphocyte injection” NCT05802693 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor T(EGFRvIII CAR-T)” NCT05802693 ↗ |
| Route | Other | “local administration (Omaya capsule administration)” NCT05802693 ↗ |